Company / Total Debt
TG Therapeutics, Inc. Total Debt History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$245.6M
FY2025
5-year range
$67.8M / $245.6M
FY2021-FY2025
Trend
+0.5%
vs FY2024
Sector context
#42 of 83
Health Care
What the data says
At $246M, TG Therapeutics, Inc.'s total debt ranks #42 of 83 in the Health Care sector. Total Debt has increased for 7 consecutive years, from $0 in FY2018 to $246M in FY2025.
Based on SEC 10-K filings.
$246M in FY2025 with a 5-year CAGR of +52.4%.
Increased from $100M to $246M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +51.2%
- 5-Year CAGR
- +52.4%
- 10-Year CAGR
- -
Sector benchmark
#42 of 83 in Health CareTop 49% of 83This company $245.6M Sector average $6.2B
▼
-96.0% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s total debt has grown for 6 consecutive years.
- 5-year CAGR of +52.4%, indicating consistent growth.
- In FY2025, total debt increased 0.5% year-over-year.
- Ranks #42 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $245.6M | +0.5% |
| FY2024 | $244.4M | +143.4% |
| FY2023 | $100.4M | +41.1% |
| FY2022 | $71.1M | +5.0% |
| FY2021 | $67.8M | +126.7% |
| FY2020 | $29.9M | +3.2% |
| FY2019 | $29.0M | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026